Drug-Eluting Stents Safe as Bare-Metal in Large-Vessel Coronary Disease
Major Finding: Rates of cardiac death or nonfatal MI infarction did not differ significantly at 2 years between patients with sirolimus-eluting stents (2.6%) and everolimus-eluting stents (3.3%); and with bare-metal stents (4.8%) of at least 3 mm in diameter.
Data Source: Multicenter study in 2,314 consecutive patients with drug-eluting stents.
Disclosures: BASKET-PROVE was sponsored by the Basel Cardiovascular Research Foundation and the Swiss National Foundation for Research. Dr. Kaiser and his coauthors report serving on the speakers bureau or as a consult/adviser for several companies, including Biotronik, Abbott Vascular, Eli Lilly, Daiichi-Sankyo, and Astra Zeneca.
FROM THE ANNUAL SCIENTIFIC SESSIONS OF THE AMERICAN HEART ASSOCIATION
Off-label stent use was high at 78% for sirolimus-eluting stents, 76% for everolimus-eluting stents and 75% for bare-metal stents.
One-third of patients had unstable angina, and two-thirds presented with acute coronary syndromes, and half of these had MI with ST-segment elevation.
BASKET-PROVE was sponsored by the Basel Cardiovascular Research Foundation and the Swiss National Foundation for Research. Dr. Kaiser and his coauthors report serving on the speakers bureau or as a consultant/adviser for several companies, including Biotronik, Abbott Vascular, Eli Lilly, Daiichi-Sankyo, and Astra Zeneca.
